Celestica is a strong company, with a remarkable and fortunate market position, but the valuation is now too high for strong ...

Treatment with 300 mg IV eptinezumab in adults with chronic migraine resulted in rapid and sustained reduction in the number of headache days that was largely sustained up to 84 weeks, according to a ...

The HHS wants to move oversight of the controversial drug discount program to the CMS, which has a more aggressive history ...